Bharat Biotech's Covaxin demonstrates 77.8 pc efficacy in Phase III trials, say sources

New Delhi: Bharat Biotech’s Covaxin has demonstrated 77.8 per cent efficacy Phase III trials data approved by the Central Drugs Standard Control Organisation, according to sources.

The company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend. Bharat Biotech’s ‘pre-submission’ meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin.

The Phase III trials data findings come shortly after two studies indicated that Covaxin produces fewer antibodies than Covishield.

Covaxin is one of the three vaccines which are currently being used in India.